177 related articles for article (PubMed ID: 19124952)
1. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model.
Takam R; Bezak E; Yeoh EE
Phys Med Biol; 2009 Feb; 54(3):611-25. PubMed ID: 19124952
[TBL] [Abstract][Full Text] [Related]
2. Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy.
Abdel-Wahab M; Reis IM; Hamilton K
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):58-68. PubMed ID: 18374503
[TBL] [Abstract][Full Text] [Related]
3. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
King CR
Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
[TBL] [Abstract][Full Text] [Related]
6. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
7. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
8. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.
Abdel-Wahab M; Reis IM; Wu J; Duncan R
Urology; 2009 Oct; 74(4):866-71. PubMed ID: 19628258
[TBL] [Abstract][Full Text] [Related]
9. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.
Jani AB; Hand CM; Lujan AE; Roeske JC; Zagaja GP; Vijayakumar S; Pelizzari CA
Med Dosim; 2004; 29(1):42-8. PubMed ID: 15023392
[TBL] [Abstract][Full Text] [Related]
10. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
11. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.
Schneider U; Lomax A; Besserer J; Pemler P; Lombriser N; Kaser-Hotz B
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):892-7. PubMed ID: 17459608
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
[TBL] [Abstract][Full Text] [Related]
13. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
14. Assessment of normal tissue complications following prostate cancer irradiation: comparison of radiation treatment modalities using NTCP models.
Takam R; Bezak E; Yeoh EE; Marcu L
Med Phys; 2010 Sep; 37(9):5126-37. PubMed ID: 20964232
[TBL] [Abstract][Full Text] [Related]
15. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
Hinnen KA; Schaapveld M; van Vulpen M; Battermann JJ; van der Poel H; van Oort IM; van Roermund JG; Monninkhof EM
J Clin Oncol; 2011 Dec; 29(34):4510-5. PubMed ID: 22025166
[TBL] [Abstract][Full Text] [Related]
16. Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer.
Hurwitz MD
Nat Clin Pract Oncol; 2008 Nov; 5(11):668-76. PubMed ID: 18825143
[TBL] [Abstract][Full Text] [Related]
17. Quality assurance of HDR prostate plans: program implementation at a community hospital.
Rush JB; Thomas MD
Med Dosim; 2005; 30(4):243-8. PubMed ID: 16275567
[TBL] [Abstract][Full Text] [Related]
18. Second primary cancers occurring after I-125 brachytherapy as monotherapy for early prostate cancer.
Musunuru H; Mason M; Murray L; Al-Qaisieh B; Bownes P; Smith J; Franks K; Carey B; Bottomley D; Henry AM
Clin Oncol (R Coll Radiol); 2014 Apr; 26(4):210-5. PubMed ID: 24507938
[TBL] [Abstract][Full Text] [Related]
19. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
20. Phenomenological modelling of second cancer incidence for radiation treatment planning.
Pfaffenberger A; Schneider U; Poppe B; Oelfke U
Z Med Phys; 2009; 19(4):236-50. PubMed ID: 19962082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]